Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines

…, D Li, A Traboulsee, PK Coyle… - American Journal …, 2006 - Am Soc Neuroradiology
MR imaging has played an important role in contributing to our understanding of the natural
history of multiple sclerosis (MS) in the brain and spinal cord, including its expression as …

The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis [RETIRED] Report of the Therapeutics and Technology Assessment Subcommittee of the …

DS Goodin, BG Arnason, PK Coyle, EM Frohman… - Neurology, 2003 - AAN Enterprises
Mitoxantrone is the first drug approved for the treatment of secondary progressive multiple
sclerosis (SPMS) in the United States. This assessment considers use of mitoxantrone in the …

Management of women with multiple sclerosis through pregnancy and after childbirth

PK Coyle - Therapeutic advances in neurological disorders, 2016 - journals.sagepub.com
Multiple sclerosis (MS) is a major acquired neurologic disease of young adults. The prototypic
patient is a young woman of reproductive age. Gender preference is becoming more …

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

…, J Corboy, J Correale, B Costell, DA Cottrell, PK Coyle… - The Lancet, 2018 - thelancet.com
Background No treatment has consistently shown efficacy in slowing disability progression
in patients with secondary progressive multiple sclerosis (SPMS). We assessed the effect of …

Randomized, comparative study of interferon β-1a treatment regimens in MS: the EVIDENCE trial

H Panitch, DS Goodin, G Francis, P Chang, PK Coyle… - Neurology, 2002 - AAN Enterprises
Background: Interferon β (IFNβ) reduces relapses and MRI activity in relapsing-remitting MS
(RRMS), with variable effects on disability. The most effective dose regimen remains …

Study and treatment of post Lyme disease (STOP-LD) A randomized double masked clinical trial

LB Krupp, LG Hyman, R Grimson, PK Coyle, P Melville… - Neurology, 2003 - AAN Enterprises
Objective: To determine whether post Lyme syndrome (PLS) is antibiotic responsive.
Methods: The authors conducted a single-center randomized double-masked placebo-controlled …

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS …

DD Mikol, F Barkhof, P Chang, PK Coyle… - The Lancet …, 2008 - thelancet.com
Background Interferon beta-1a and glatiramer acetate are commonly prescribed for
relapsing-remitting multiple sclerosis (RRMS), but no published randomised trials have directly …

Fatigue therapy in multiple sclerosis: results of a double‐blind, randomized, parallel trial of amantadine, pemoline, and placebo

LB Krupp, PK Coyle, C Doscher, A Miller, AH Cross… - Neurology, 1995 - AAN Enterprises
Objective To determine the relative efficacy of amantadine, pemoline, and placebo in treatment
of multiple sclerosis (MS)-related fatigue. Background Fatigue is a complication of MS. …

Transthyretin sequesters amyloid beta protein and prevents amyloid formation.

…, KH Weisgraber, PK Coyle - Proceedings of the …, 1994 - National Acad Sciences
The cardinal pathological features of Alzheimer disease are depositions of aggregated amyloid
beta protein (A beta) in the brain and cerebrovasculature. However, the A beta is found …

Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double‐blind, placebo‐controlled trial

…, PA Narayana, P O'Connor, PK Coyle… - Annals of …, 2007 - Wiley Online Library
Objective To determine whether glatiramer acetate (GA) slows accumulation of disability in
primary progressive multiple sclerosis. Methods A total of 943 patients with primary …